Px563L: Phase Ia data

A double-blind, placebo-controlled, U.S. Phase Ia trial in about 54 healthy volunteers showed that 2 doses of 10 or 80 ug intramuscular Px563L given 28 days apart led to a TNA NF50 value of >=0.56 at ...